Teriflunomide in multiple sclerosis: an update

Keyphrases

• Multiple Sclerosis 100%
• Teriflunomide 100%
• TEMSO 60%
• Disability 40%
• Phase II Study 40%
• Disease-modifying Therapy 40%
• Once-daily 20%
• Atrophy 20%
• Phase II Trial 20%
• Patient-Reported Outcomes Measurement Information System (PROMIS) 20%
• Multiple Patients 20%
• Image Evaluation 20%
• Long-term Extension 20%
• MRI Outcomes 20%
• Structural Image 20%
• Oral Disease-modifying Therapy 20%
• Supplementary Measures 20%

Medicine and Dentistry

• Multiple Sclerosis 100%
• Teriflunomide 100%
• Disease Modifying Therapy 60%
• Magnetic Resonance Imaging 20%
• Patient-Reported Outcome 20%
• Oral Submucous Fibrosis 20%

Neuroscience

• Multiple Sclerosis 100%
• Teriflunomide 100%
• Magnetic Resonance Imaging 20%
• Oral Disease 20%